| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Adjuvant endocrine therapy for premenopausal women: risk stratification, type and duration1
|
Francis, Prudence A.
|
|
|
48 |
S1 |
p. S85-S88
|
artikel
|
| 2 |
Adjuvant endocrine therapy in postmenopausal women: making treatment choices based on the magnitude of benefit1
|
Burstein, Harold J.
|
|
|
48 |
S1 |
p. S89-S91
|
artikel
|
| 3 |
Breast cancer survivorship care beyond local and systemic therapy1
|
Sheng, Jennifer Y.
|
|
|
48 |
S1 |
p. S103-S109
|
artikel
|
| 4 |
Clinical Benefit in the Treatment of Patients with Early Breast Cancer1
|
Sella, Tal
|
|
|
48 |
S1 |
p. S115-S118
|
artikel
|
| 5 |
Clinical benefits of bone targeted agents in early breast cancer1
|
Coleman, Robert
|
|
|
48 |
S1 |
p. S92-S96
|
artikel
|
| 6 |
Emerging strategies in neoadjuvant treatment of patients with HER2-positive early breast cancer1
|
Harbeck, Nadia
|
|
|
48 |
S1 |
p. S97-S102
|
artikel
|
| 7 |
Endocrine therapy resistance: new insights 1
|
Lei, Jonathan T.
|
|
|
48 |
S1 |
p. S26-S30
|
artikel
|
| 8 |
Estimating the magnitude of clinical benefit from (neo)adjuvant chemotherapy in patients with ER-positive/HER2-negative breast cancer1
|
McCartney, Amelia
|
|
|
48 |
S1 |
p. S81-S84
|
artikel
|
| 9 |
Estimating the magnitude of clinical benefit of local therapy in patients with DCIS1
|
Hwang, E. Shelley
|
|
|
48 |
S1 |
p. S34-S38
|
artikel
|
| 10 |
Estimating the magnitude of clinical benefit of systemic therapy in patients with DCIS or pre-invasive disease of the breast1
|
Lazzeroni, Matteo
|
|
|
48 |
S1 |
p. S39-S43
|
artikel
|
| 11 |
Future options: the potential role of proton irradiation1
|
Maduro, John Henry
|
|
|
48 |
S1 |
p. S76-S80
|
artikel
|
| 12 |
Identifying research priorities in the treatment of patients with early breast cancer: from the patient perspective1
|
Pritchard, Kathleen I.
|
|
|
48 |
S1 |
p. S21-S22
|
artikel
|
| 13 |
Impact of older age on local treatment decisionss1
|
Ugurlu, M. Umit
|
|
|
48 |
S1 |
p. S57-S61
|
artikel
|
| 14 |
Individualised target volume selection and dose prescription after conservative surgery, mastectomy and reconstruction1
|
Chua, Boon H
|
|
|
48 |
S1 |
p. S69-S75
|
artikel
|
| 15 |
Is prophylactic mastectomy justified in women without BRCA mutation?1
|
Rutgers, Emiel J.T.
|
|
|
48 |
S1 |
p. S62-S64
|
artikel
|
| 16 |
News in surgery of patients with early breast cancer1
|
Montagna, Giacomo
|
|
|
48 |
S1 |
p. S2-S6
|
artikel
|
| 17 |
Optimizing Early Breast Cancer Therapies – the 2019 St. Gallen International Breast Cancer Consensus Conference in Vienna1
|
Gnant, Michael
|
|
|
48 |
S1 |
p. S1
|
artikel
|
| 18 |
Regional nodal irradiation for early breast cancer; clinical benefit according to risk stratification1
|
Bartelink, Harry
|
|
|
48 |
S1 |
p. S65-S68
|
artikel
|
| 19 |
Research priorities in prediction of response in early breast cancer1
|
Carey, Lisa A.
|
|
|
48 |
S1 |
p. S31-S33
|
artikel
|
| 20 |
Risk stratification according to stage and pathology1
|
Regan, Meredith M.
|
|
|
48 |
S1 |
p. S23-S25
|
artikel
|
| 21 |
Standard and controversies in sentinel node in breast cancer patients1
|
Veronesi, P.
|
|
|
48 |
S1 |
p. S53-S56
|
artikel
|
| 22 |
Systemic treatment of patients with early breast cancer: recent updates and state of the art1
|
Caparica, Rafael
|
|
|
48 |
S1 |
p. S7-S20
|
artikel
|
| 23 |
Targeting immune pathways in breast cancer: review of the prognostic utility of TILs in early stage triple negative breast cancer (TNBC)1
|
Blackley, Elizabeth F
|
|
|
48 |
S1 |
p. S44-S48
|
artikel
|
| 24 |
Treatment selection for patients with equivocal HER2 status and in luminal versus HER2-enriched disease1
|
Viale, Giuseppe
|
|
|
48 |
S1 |
p. S49-S52
|
artikel
|
| 25 |
Will surgery be a part of breast cancer treatment in the future?1
|
Monica Morrow, MD
|
|
|
48 |
S1 |
p. S110-S114
|
artikel
|
Tijdschrift beschrijving